Sabby Management, LLC Biovie Inc. Transaction History

Sabby Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.4 - $0.56 $17,568 - $24,595	43,920 Added 6.37%	733,055 $293,000
Q1 2024 May 15, 2024	BUY	$0.53 - $1.89 $365,241 - $1.3 Million	689,135 New	689,135 $365,000
Q3 2022 Nov 14, 2022	SELL	$1.38 - $25.6 $730,464 - $13.6 Million	-529,322 Reduced 84.37%	98,048 $244,000
Q2 2022 Aug 15, 2022	BUY	$1.44 - $5.04 $20,816 - $72,858	14,456 Added 2.36%	627,370 $910,000
Q1 2022 May 16, 2022	SELL	$2.74 - $5.65 $96,806 - $199,620	-35,331 Reduced 5.45%	612,914 $2.89 Million
Q4 2021 Feb 14, 2022	BUY	$4.41 - $6.99 $632,323 - $1 Million	143,384 Added 28.4%	648,245 $2.92 Million
Q3 2021 Nov 15, 2021	BUY	$6.69 - $16.93 $3.38 Million - $8.55 Million	504,861 New	504,861 $3.38 Million

340K

Ticker BIVI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 30,165,300
Market Cap $68.5M
Description
BioVie Inc., a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, which completed Phase IIa clinical trial for the treatment of ascites due to chronic liver cirrhosis; and NE3107, which is in Phase III clinical trial ...

Get notified when there are updates to the investment portfolio of Sabby Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Sabby Management, LLC with notifications on news.